Your browser doesn't support javascript.
Immunothérapie: aussi chez le patient âgé ? / [Immunotherapy: also in elderly patients ?]
Rev Med Suisse ; 15(660): 1512-1515, 2019 Aug 28.
Artigo em Francês | MEDLINE | ID: mdl-31496176
The emergence of immunotherapy has generated great enthusiasm in oncology improving the prognosis of pathologies such as melanoma, lung cancer, kidney cancer, bladder and head and neck cancers. This enthusiasm concerns also older patients in view of the good tolerance of immunotherapy in young people. However, advanced age is linked to changes in the immune system, called immunosenescence, which could have a negative impact on the efficacy and toxicity of immunotherapy treatment. Knowledge in terms of efficacy and tolerance is limited for geriatric patients, few being included in clinical studies. This article summarizes the experience of immunotherapy in large clinical trials. It appears that the immune checkpoint inhibitors are effective and well tolerated in the elderly.





Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Aspecto clínico: Prognóstico Limite: Humanos Idioma: Francês Revista: Rev Med Suisse Assunto da revista: Medicina Ano de publicação: 2019 Tipo de documento: Artigo